It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Several computational methods have been developed to identify neutralizing antibodies (NAbs) covering four dengue virus serotypes (DENV-1 to DENV-4); however, limitations of the dataset and the resulting performance remain. Here, we developed a new computational framework to predict potent and stable NAbs against DENV-1 to DENV-4 using only antibody (CDR-H3) and epitope sequences as input. Specifically, our proposed computational framework employed sequence-based ML and molecular dynamic simulation (MD) methods to achieve more accurate identification. First, we built a novel dataset (n = 1108) by compiling the interactions of CDR-H3 and epitope sequences with the half maximum inhibitory concentration (IC50) values, which represent neutralizing activities. Second, we achieved an accurately predictive ML model that showed high AUC values of 0.879 and 0.885 by tenfold cross-validation and independent tests, respectively. Finally, our computational framework could be applied to filter approximately 2.5 million unseen antibodies into two final candidates that showed strong and stable binding to all four serotypes. In addition, the most potent and stable candidate (1B3B9_V21) was evaluated for its development potential as a therapeutic agent by molecular docking and MD simulations. This study provides an antibody computational approach to facilitate the high-throughput identification of NAbs and accelerate the development of therapeutic antibodies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Khon Kaen University, Department of Microbiology, Faculty of Medicine, Khon Kaen, Thailand (GRID:grid.9786.0) (ISNI:0000 0004 0470 0856)
2 Chiang Mai University, Modern Management and Information Technology, College of Arts, Media and Technology, Chiang Mai, Thailand (GRID:grid.7132.7) (ISNI:0000 0000 9039 7662)
3 Mahidol University, Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Bangkok, Thailand (GRID:grid.10223.32) (ISNI:0000 0004 1937 0490)
4 Khon Kaen University, Department of Biochemistry, Faculty of Medicine, Khon Kaen, Thailand (GRID:grid.9786.0) (ISNI:0000 0004 0470 0856)
5 Khon Kaen University, Department of Microbiology, Faculty of Medicine, Khon Kaen, Thailand (GRID:grid.9786.0) (ISNI:0000 0004 0470 0856); Khon Kaen University, Research and Diagnostic Center for Emerging Infectious Diseases, Khon Kaen, Thailand (GRID:grid.9786.0) (ISNI:0000 0004 0470 0856)
6 Chulalongkorn University, Center of Excellent in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Bangkok, Thailand (GRID:grid.7922.e) (ISNI:0000 0001 0244 7875)